Chordoma of Sacrum and Vertebral Bodies Overview
Chordoma of Sacrum and Vertebral Bodies Overview Chordoma of the sacrum and vertebral bodies is a rare and intriguing type of malignant tumor that originates from remnants of the notochord, an embryonic structure that plays a crucial role in the development of the spine. Despite its rarity, accounting for approximately 1-4% of all primary bone tumors, chordomas present unique challenges in diagnosis and management due to their location and biological behavior.
These tumors most frequently occur along the axial skeleton, with the sacrum being the most common site, followed by the skull base and the mobile spine, including cervical, thoracic, and lumbar regions. Sacral chordomas tend to grow slowly but locally invasive, often extending into adjacent soft tissues and causing symptoms such as lower back pain, numbness, or bowel and bladder dysfunction. Because of their indolent growth pattern, they may go unnoticed for extended periods, leading to larger tumor sizes at the time of diagnosis. Chordoma of Sacrum and Vertebral Bodies Overview
Chordoma of Sacrum and Vertebral Bodies Overview Histologically, chordomas are characterized by the presence of physaliphorous cells—large cells with bubbly, vacuolated cytoplasm embedded within a myxoid matrix. These features, combined with immunohistochemical markers such as brachyury, cytokeratins, and S-100 protein, help distinguish chordomas from other similar tumors like chondrosarcomas or metastatic carcinomas.
Imaging studies play a vital role in diagnosis. Magnetic resonance imaging (MRI) is the modality of choice, providing detailed information about the tumor‘s extent and relation to the spinal cord, nerve roots, and surrounding tissues. Typically, chordomas appear as lobu
lated, T2 hyperintense masses with variable enhancement post-contrast. Computed tomography (CT) scans are useful for assessing bone destruction and planning surgical approaches. Chordoma of Sacrum and Vertebral Bodies Overview
Surgical excision remains the primary treatment modality. The goal is complete resection with negative margins, as this significantly reduces the risk of recurrence. However, due to the tumor’s location and proximity to critical structures, achieving wide margins can be challenging. En bloc resection, often involving partial or total sacrectomy, is preferred when feasible. Postoperative radiotherapy, especially high-dose conformal or proton beam therapy, is commonly employed to improve local control, given the tumor’s relative radioresistance.
The prognosis of sacral and spinal chordomas depends heavily on the extent of resection and tumor size at diagnosis. While they are locally aggressive and prone to recurrence, distant metastases are relatively uncommon but can occur, particularly in the lungs or liver. Regular follow-up with imaging is essential for early detection of recurrence. Chordoma of Sacrum and Vertebral Bodies Overview
Advances in targeted therapies and newer radiotherapy techniques continue to evolve, providing hope for better management and outcomes. Multidisciplinary approaches involving surgeons, radiologists, oncologists, and pathologists are crucial for optimizing care. Despite their challenging nature, early diagnosis and comprehensive treatment strategies can significantly improve the quality of life and survival outcomes for patients with sacral and vertebral chordomas. Chordoma of Sacrum and Vertebral Bodies Overview